Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Travere Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
ADC Therapeutics SA June 1, 202699.4%
-
Travere Therapeutics Inc. May 19, 202698.6%
-
ADC Therapeutics SA June 3, 202599.7%
-
Travere Therapeutics Inc. May 15, 202599.1%
-
ADC Therapeutics SA June 13, 202496.9%
-
Travere Therapeutics Inc. May 8, 202489.1%
-
Travere Therapeutics Inc. May 17, 202395.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 3, 2026 | ADC Therapeutics SA | Shares withheld for tax | −15,196 | $3.08 | $46,804 |
| Jun 1, 2026 | ADC Therapeutics SA | Grant or award | +45,000 | — | — |
| May 19, 2026 | Travere Therapeutics Inc. | Grant or award | +4,000 | — | — |
| Jun 13, 2025 | ADC Therapeutics SA | Shares withheld for tax | −15,184 | $3.58 | $54,359 |
| Jun 3, 2025 | ADC Therapeutics SA | Grant or award | +40,000 | — | — |
| May 15, 2025 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| Jun 17, 2024 | ADC Therapeutics SA | Open-market sale | −6,995 | $2.89 | $20,216 |
| Jun 13, 2024 | ADC Therapeutics SA | Grant or award | +40,000 | — | — |
| May 8, 2024 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| May 17, 2023 | Travere Therapeutics Inc. | Grant or award | +4,500 | — | — |
Questions about Ron Squarer
What boards is Ron Squarer on?
Ron Squarer sits on the boards of ADC Therapeutics SA and Travere Therapeutics Inc.
How long has Ron Squarer served on boards?
Our records show at least 6 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.